Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

21.71 -0.62 (-2.77%)
Streaming Delayed Price Updated: 9:41 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
Via AB Newswire
News headline image
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming Investor Conferences
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Infinimmune Announces Research Collaboration with Immunome
From Infinimmune
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming Investor Conferences
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming March Conferences
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>